Oncology

News

Close-up image of a firm handshake between two colleagues

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

News

AZ reportedly mulls biggest-ever pharma merger with Gilead

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <

News

Sanofi's multiple myeloma drug approved in EU

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex

Oncology

Preparing for the next decade of innovation in immuno-oncolo...

Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.

Oncology

ASCO 2020 virtual annual meeting - day 3

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into the third and final

News

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AZ reportedly mulls biggest-ever pharma merger with Gilead

Sanofi's multiple myeloma drug approved in EU

Preparing for the next decade of innovation in immuno-oncolo...

ASCO 2020 virtual annual meeting - day 3

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

FDA relents and will review Moderna's flu shot

How to meet your physicians where they are online

Oncology

Editor's Picks